
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GANX · as of Jun 9, 2026
Key Statistics
Explore Gain Therapeutics, Inc. Data
ganx stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 8 · Buy rate: 87.5%
The GANX analyst consensus is Buy, based on ratings from 8 Wall Street analysts over the past 3 months. The average 12-month price target is $10.00, representing +491.72% upside from the current price of $1.69.
Competitors & Peers
ganx competitorsStock Performance
Full HistoryAbout Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its effort…
what is gain therapeutics, inc. · ganx stock overview · gain therapeutics, inc. company profile · who is gain therapeutics, inc. ceo · ganx NASDAQ · gain therapeutics, inc. headquarters · gain therapeutics, inc. business segments
About Stock Overview & Key Data
Gain Therapeutics, Inc. (GANX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 19, 2021. As of the latest trading session, GANX stock price is $1.69, with a market capitalization of $72.1M. The stock has returned -11.52% over the past 12 months and -47.52% year-to-date.
According to 8 Wall Street analysts, the consensus rating for Gain Therapeutics, Inc. stock is Buy, with an average 12-month price target of $10.00. In fiscal year 2025, Gain Therapeutics, Inc. reported revenue of — and net income of -$20.2M. For detailed data — including Gain Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Gain Therapeutics, Inc. (GANX) stock price is $1.69. The stock is traded on NASDAQ under the ticker symbol GANX. The 52-week range is $1.41 – $4.34.